Leukemia rivals try to stay ahead as Merck, Lilly chase

The launch of AbbVie and Johnson & Johnson's Imbruvica transformed treatment of the blood cancer chronic lymphocytic leukemia, helping patients stay disease free for years with a pill rather than chemotherapy combinations.